Anti-VEGF Receptor 2 (phospho Y1054 + Y1059)抗体(ab5473)
Key features and details
- Rabbit polyclonal to VEGF Receptor 2 (phospho Y1054 + Y1059)
- Suitable for: ICC, WB
- Reacts with: Human
- Isotype: IgG
产品名称Anti-VEGF Receptor 2 (phospho Y1054 + Y1059)抗体
参阅全部 VEGF Receptor 2 一抗
描述兔多克隆抗体to VEGF Receptor 2 (phospho Y1054 + Y1059)
经测试应用适用于: ICC, WBmore details
预测可用于: Mouse, Rat
Synthetic peptide corresponding to Human VEGF Receptor 2 (phospho Y1054 + Y1059).
- ICC: VEGF treated HUVEC whole cells. WB: VEGF treated HUVEC, MDA-MB-231 and MCF7 whole cell extract.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
存放说明Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Preservative: 0.05% Sodium azide
Constituents: PBS, 0.1% BSA, 50% Glycerol
Concentration information loading...
纯度Immunogen affinity purified
纯化说明The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated VEGFR 2. The final product is generated by affinity chromatography using a VEGFR 2 derived peptide that is phosphorylated at Tyrosines 1054 and 1059.
The Abpromise guarantee
1/1000. Detects a band of approximately 200 kDa.
1/1000. Detects a band of approximately 200 kDa.
功能Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
疾病相关Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
序列相似性Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
翻译后修饰Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
- Information by UniProt
- Entrez Gene: 3791 Human
- Entrez Gene: 16542 Mouse
- Entrez Gene: 25589 Rat
- Omim: 191306 Human
- SwissProt: P35968 Human
- SwissProt: P35918 Mouse
- SwissProt: O08775 Rat
- Unigene: 479756 Human
- CD309 antibody
- CD309 antigen antibody
- EC 22.214.171.124 antibody
Immunofluorescence analysis of HUVEC cells labelling VEGF Receptor 2 (phospho Y1054 + Y1059) (PAnel a: green) using ab5473 at 2 ug/ml in 0.1% BSA for 3 hours at room temperature, follwed by Alexa Fluor® 488-conjugated Goat anti-rabbit IgG polyclonal at 1/2000 dilution. Pbel b: Nuclei stained with DAPI (blue), Panel c: F-actin stained with Alexa Fluor® 555 Rhodamine Phalloidin (red), Panel d: Merged images. The images were captured at 60X magnification.
Prior antibody incubation, HUVEC (Human umbilical vein endothelial cell line) cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes and blocked with 1% BSA for 1 hour at room temperature, followed by treatment with 100 ng of VEGF for 30 minutes. Assay was done on 90% confluent log phase HUVEC cells.
All lanes : Anti-VEGF Receptor 2 (phospho Y1054 + Y1059) antibody (ab5473) at 1/1000 dilution
Lane 1 : HUVEC (Human umbilical vein endothelial cell line) whole cell extract with Skimmed milk
Lane 2 : HUVEC cells treated with 25ng/ml VEGF for 5 minutes with Skimmed milk
Lane 3 : MDA-MB-231 (human breast adenocarcinoma cell line) whole cell extract with Skimmed milk
Lane 4 : MCF7 (human breast adenocarcinoma cell line) whole cell extract with Skimmed milk
Lysates/proteins at 30 µg per lane.
Blocking peptides at 5 % per lane.
All lanes : Goat anti-rabbit IgG HRP conjugate at 1/5000 dilution
A 130 kDa band corresponding to VEGFR (pYpY1054/1059) was observed across cell lines tested.
Protein samples were electrophoresed using Novex® NuPAGE® 10 % Bis-Tris gel, XCell SureLock™ Electrophoresis System and Novex® Sharp Pre-Stained Protein Standard.
Resolved proteins were then transferred onto a nitrocellulose membrane by over night wet transfer.
Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate.
ab5473 被引用在 36 文献中.
- Wu Y et al. CircLATS2 Regulates miR-520a-3p/E2F7/p-VEGFR2 Signaling Pathway to Promote Hepatocellular Carcinoma Progression and Angiogenesis. J Oncol 2022:3744560 (2022). PubMed: 35444695
- Lu K et al. Dopamine Prevents Ultraviolet B-induced Development and Progression of Premalignant Cutaneous Lesions through its D2 Receptors. Cancer Prev Res (Phila) 14:687-696 (2021). PubMed: 33846213
- Ma S et al. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep 36:109549 (2021). PubMed: 34407412
- Arpino JM et al. Low-flow intussusception and metastable VEGFR2 signaling launch angiogenesis in ischemic muscle. Sci Adv 7:eabg9509 (2021). PubMed: 34826235
- Noh JJ et al. Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer. Pharmaceutics 12:N/A (2020). PubMed: 33086573